Alpha Tau Medical Ltd【DRTS】株式ニュース

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

Alpha Tau to Present at the Jefferies Global Healthcare Conference

JERUSALEM, May 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:...

Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

- Presented preclinical data demonstrating abscopal immune effect in pancreatic murine tumor models at ESTRO...

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer

JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:...

Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow

- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from...

Alpha Tau to Participate in May Investor Conferences

JERUSALEM, May 01, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:...

Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit

JERUSALEM, March 25, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update

- Positive interim safety and feasibility data from pancreatic cancer study in Montreal, with initial signs of...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference

JERUSALEM, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference

- The overview presentation will review some of the Company’s recent achievements, including highly promising...

Form 144 - Report of proposed sale of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

PonkenPlonken 12時間前

https://www.ourcrowd.com/startup-news/alpha-tau-100-complete-response-rate-in-skin-cancer-trial?
might become SOC in inoperable tumors - super tech - revolutionize radio

👍️0

PonkenPlonken 13時間前

has a lot of critical readouts coming soon - see below
neglected and forgotten...

👍️0

PonkenPlonken 5日前

https://www.alphatau.com/single-post/alpha-tau-healthcare-capital-corp-to-combine-and-create-a-1-billion-publicly-traded-company

👍️0

PonkenPlonken 3週前

Great Israeli company -- coming to life ahead of a few readouts

👍️0

theswordman 1月前

3rd QTR update: 2+ years op cash. Trial expansion.
FDA accepted for TAP--Total Product Life Cycle Advisory Program (TAP)
FDA approval of an Investigational Device Exemption (IDE) application for cSCC

https://www.alphatau.com/single-post/alpha-tau-medical-announces-third-quarter-2024-financial-results-and-provides-corporate-update

👍️0

theswordman 2月前

AlphaTau into the FDAs TPLC program: https://www.alphatau.com/single-post/alpha-tau-announces-acceptance-into-fda-s-total-product-life-cycle-advisory-program-to-accelerate-ma

Here is link that explains what that program helps with : https://www.fda.gov/medical-devices/how-study-and-market-your-device/total-product-life-cycle-advisory-program-tap

👍️0

theswordman 2月前

1st lung cancer patient treated--https://www.alphatau.com/single-post/alpha-tau-treats-first-patient-with-recurrent-lung-cancer

“The treatment makes use of bronchoscopic endobronchial ultrasound to insert the Alpha DaRT sources.

examining its application to an organ such the lung, given its proximity to vital healthy organs, may hopefully open new doors to a global population of patients with otherwise poor treatment options

👍️0

theswordman 3月前

Emory Univ wants another trial for subpopulation

https://www.alphatau.com/single-post/fda-approval-of-ide-to-initiate-multi-center-investigator-initiated-study-of-alpha-dart-in-immunoco

👍️0

theswordman 3月前

The big boys are correct. Just a little off ontheir delivery and MOA

https://www.cnbc.com/2024/09/16/radiopharmaceuticals-race-heats-up-as-drugmakers-chase-novartis.html

👍️0

theswordman 4月前

2nd qtr update

https://www.alphatau.com/single-post/alpha-tau-medical-announces-second-quarter-2024-financial-results-and-provides-corporate-update

👍️0

theswordman 5月前

Atlanta TV discussing AlphaDart trial at Emory Univ.

https://www.atlantanewsfirst.com/2024/06/25/emory-doctor-hopeful-about-clinical-trial-new-skin-cancer-treatment/

https://clinicaltrials.gov/study/NCT05323253?term=alpha%20tau&intr=alpha%20dart&page=2&rank=20#study-overview

👍️0

theswordman 6月前

Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

https://www.alphatau.com/single-post/alpha-tau-announces-publication-in-cancers-journal-of-long-term-safety-and-efficacy-data-in-multiple

https://www.alphatau.com/single-post/alpha-tau-medical-announces-first-quarter-2024-financial-results-and-provides-corporate-update

👍️0

theswordman 7月前

https://www.alphatau.com/single-post/alpha-tau-announces-alpha-dart-treatment-of-first-patient-with-liver-metastases-of-colorectal-cancer

👍️0

theswordman 8月前

Bassett is one of two Alpha DaRT trial sites in New York State, the other being Memorial Sloan Kettering Cancer Center in New York City.

https://www.allotsego.com/skin-cancer-treatment-trials-open/

👍️0

theswordman 8月前

March Investor Deck

https://www.alphatau.com/_files/ugd/89ab89_701f2ad74a4c4684b223cb427cf79506.pdf

👍️0

theswordman 1年前

AlphaTau--Sidoti Conference

https://www.alphatau.com/single-post/alpha-tau-to-participate-in-sidoti-small-cap-conference

OR

https://www.meetmax.com/sched/event_98459/conference_presentations.html?bank_access=0&event_id=98459

This is from 07 DEC (THURS) @ 9:15 AM

👍️0

theswordman 1年前

Pancreatic Cancer Trial--early results
https://www.alphatau.com/single-post/highly-promising-interim-results-of-alpha-dart-treatment-of-advanced-pancreatic-cancer

👍️0

theswordman 1年前

Japan’s Pharmaceuticals and Medical Devices Agency (“PMDA”) has accepted Alpha Tau’s submission requesting shonin pre-market approval of Alpha DaRT in patients with recurrent head & neck cancer

https://www.alphatau.com/single-post/atm-submits-to-japanese-pmda-for-pre-market-approval-of-alpha-dart-for-recurrent-head-neck-cancer

👍️0

theswordman 1年前

CORP UPDATE

https://finance.yahoo.com/news/alpha-tau-medical-announces-third-213000260.html?.tsrc=rss

👍️0

theswordman 1年前

New video presentation. Updates about Hahn@SAB. New manuf facility.

👍️0

theswordman 1年前

Alpha Tau adds another manuf facility in U.S. So this is certainly getting ahead (cart before the horse??)
https://www.alphatau.com/single-post/atm-enters-into-long-term-lease-of-site-in-new-hampshire-for-second-u-s-manufacturing-facility

The Hudson site promises to be larger than our existing Lawrence site, and is expected to support our goals of materially scaling up capacity as well as achieving manufacturing redundancy

👍️0

theswordman 1年前

Hahn joins Science Advisor Board

https://www.marketscreener.com/quote/stock/ALPHA-TAU-MEDICAL-LTD-134583875/news/Alpha-Tau-Medical-Ltd-Announces-Stephen-M-Hahn-Joins-Scientific-Advisory-Board-45136482/

👍️0

theswordman 1年前

Latest DRTS presentation

👍️0

theswordman 1年前

2nd patient treated for inoperable pancreatic cancer. 1St was in Montreal

https://www.globenewswire.com/news-release/2023/09/14/2743253/0/en/Alpha-Tau-Treats-First-Patient-with-Advanced-Inoperable-Pancreatic-Cancer-at-Israel-s-Hadassah-Medical-Center.html

👍️0

Awl416 1年前

Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT

CORP UPDATE

https://www.alphatau.com/single-post/alpha-tau-medical-announces-first-quarter-2023-financial-results-and-provides-corporate-update

👍️0

theswordman 2年前

With our Breakthrough Device Designation for the treatment of certain patients with squamous cell carcinoma, we look forward to swift accrual into our U.S. pivotal ReSTART trial, with the goal of bringing the Alpha DaRT closer to availability for patients as quickly as possible."

The results of the trial demonstrated that the treatment was successfully delivered to ten of ten patients, with a 100% CR observed at 12 and 24 weeks,

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2804784

👍️0

theswordman 2年前

New buy rating

https://beststocks.com/alpha-tau-medical-receives-buy-rating-and-hig/

👍️0

theswordman 2年前

Alpha Tau enrolled the 1st patrient in their 30 patient pancreatic cancer trial

https://www.clinicaltrials.gov/ct2/show/NCT04002479.

Read about the milestone here

https://www.alphatau.com/single-post/alpha-tau-jgh-announce-alpha-dart-treatment-of-first-patient-in-pancreatic-cancer-clinical-trial

Treatment of 1st two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial

https://www.alphatau.com/single-post/treatment-of-1st-two-patients-in-its-pivotal-multicenter-recurrent-skin-cancer-restart-trial

👍️0

theswordman 2年前

Cash & equivalents balance of $105.4 million, with runway for at least two years

https://www.alphatau.com/single-post/alpha-tau-medical-announces-full-year-2022-financial-results-and-provides-corporate-update

👍️0

theswordman 2年前

https://www.alphatau.com/single-post/health-canada-authorization-for-alpha-dart-clinical-trial-for-the-treatment-of-liver-metastases

👍️ 1

theswordman 2年前

100% response rate!!!!!!!!!!!!!!!!!!!!!!!!!

👍️0

theswordman 2年前

Several good pieces of news

https://newsfilter.io/a/265287a70404d81a19c29eab7e95abca

👍️0

theswordman 2年前

Alpha Tau Medical Ltd. (the “Company”) hereby furnishes the following documents:

(i) notice and proxy statement with respect to the Company’s annual general meeting of shareholders (the “Meeting”) to be held at 4:30 p.m. (Israel time), on November 2, 2022, at the Company’s headquarters at 5 Kiryat Hamada St., Jerusalem 9777605, Israel, describing proposals to be voted upon at the Meeting, the procedure for voting in person or by proxy at the Meeting and various other details related to the Meeting; and
(ii) a proxy card for use in connection with the Meeting.

The proxy statement is furnished with this report of foreign private issuer on Form 6-K (this “Form 6-K”) as Exhibit 99.1 and the proxy cards are furnished with this Form 6-K Exhibits 99.2 and 99.3.

This Form 6-K is incorporated by reference into the Company’s registration statement on Form S-8 (File No. 333-264169).

👍️0

theswordman 2年前

GOOD READ!!!

https://medium.com/wadepthealth/washington-is-one-of-first-states-to-license-promising-new-cancer-treatment-59c42162e25b

👍️0

theswordman 2年前

18 JUL--11 AM EASTERN--free to register

https://finance.yahoo.com/news/alpha-tau-hosting-key-opinion-200100611.html

👍️0

theswordman 2年前

Patient, 60, is given alpha-radiation to target the tumor without harming healthy tissue in ‘historical’ procedure

https://nocamels.com/2022/06/israeli-researchers-use-breakthrough-tech-to-treat-prostate-cancer-for-first-time/

👍️0

theswordman 3年前

1st Prostate Cancer patient treated!!!!

https://www.prnewswire.com/news-releases/alpha-tau-announces-treatment-of-first-prostate-cancer-patient-with-alpha-dart-301573470.html

👍️0

theswordman 3年前

On June 16, 2022, Alpha Tau Medical Ltd. (the “Company”) issued a press release titled “Alpha Tau Announces Receipt of Radioactive License to Allow Production in Main Manufacturing Floor at its Jerusalem Site, Amended Radioactive License with Increased Capacity at Lawrence, MA Site.” A copy of this press release is attached to this Form 6-K as Exhibit 99.1.

https://newsfilter.io/a/90df70ad4fbbeb233fae5d6cea6e9dce

👍️0

theswordman 3年前

https://www.prnewswire.com/news-releases/alpha-tau-announces-fda-approval-of-ide-to-initiate-multi-center-pivotal-study-of-alpha-dart-in-recurrent-cutaneous-scc-301564017.html

👍️0

theswordman 3年前

NEW MAY 2022 INVESTOR PRESENTATION

Link goes to webpage for PDF download

https://www.alphatau.com/events

👍️0

theswordman 3年前

DRTS: Alpha Tau: First Alpha DaRT Patients Treated in France as Part of Alpha DaRT Multicenter Skin Cancer Trial

https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20220523090518DRTS&utm_campaign=inplay&utm_medium=social&utm_source=twitter&utm_content=view_page

👍️0

theswordman 3年前

Form F-1 filed

https://newsfilter.io/a/a2246fdd4e4ed658cd4c86741101f8c0

👍️0

theswordman 3年前

CantorFitz initiates coverage of AlphaTau

https://biotuesdays.com/2022/04/14/cantor-starts-alpha-tau-medical-at-ow-pt-20/

👍️0

theswordman 3年前

https://seekingalpha.com/article/4500989-alpha-tau-treating-cancer-with-precision-alpha-radiation?utm_source=stck.pro&utm_medium=referral

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター